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Purpose: To describe the radiological findings of radiation-induced lung damage (RILD) present on 
CT imaging of lung cancer patients 12 months after radical chemoradiation. 
 
Material and Methods: Baseline and 12-month CT scans of 33 patients were reviewed from a phase 
I/II clinical trial of isotoxic chemoradiation (IDEAL CRT). CT findings were scored in three 30 
categories derived from eleven sub-categories: (1) parenchymal change, defined as the presence of 
consolidation, ground-glass opacities (GGOs), traction bronchiectasis and/or reticulation; (2) lung 
volume reduction, identified through reduction in lung height and/or distortions in fissures, 
diaphragm, anterior junction line and major airways anatomy, and (3) pleural changes, either 
thickening and/or effusion.   35 
 
Results: Six patients were excluded from the analysis due to anatomical changes caused by partial 
lung collapse and abscess. All remaining 27 patients had radiological evidence of lung damage. The 
three categories, parenchymal change, shrinkage and pleural change were present in 100%, 96% and 
82% respectively. All patients had at least two categories of change present and 72% all three. GGOs, 40 
reticulation and traction bronchiectasis were present in 37%, 52% and 44% of patients.  
 
Conclusions: Parenchymal change, lung shrinkage and pleural change are present in a high 
proportion of patients and are frequently identified in RILD. GGOs, reticulation and traction 









Radiation-induced lung damage (RILD) is a side effect of radical radiotherapy (RT) and a significant 
cause of reduced quality of life in cancer survivors[1]. While the early, acute phase has been 55 
extensively investigated, the late, chronic phase of RILD is less well studied and described [2–6]. The 
historically poor prognosis of lung cancer patients has led to a lack of objective and standardised 
criteria to describe and quantify the process [4,7,8], leading to variable reporting across centres and 
trials. As lung cancer survivorship improves, the importance of long term treatment side effects grows 
[9–14].  60 
 
Repetitive or severe lung injuries result in permanent radiological scarring, often referred to as 
fibrosis, that impairs lung function [15]. CT imaging is a sensitive indicator of RILD [16–22]. In 
addition to parenchymal density changes many other related abnormalities exist that are under-
reported in the literature and poorly understood [5,17,20,21,23–29]. These include more obvious 65 
changes such as segmental collapse and pleural effusions, and more subtle changes such as traction 
bronchiectasis, elevation or tenting of the hemidiaphragm, mediastinal shift and rotation, distortion of 
major airways and pleural thickening.  
 
Using patient data from the completed IDEAL CRT trial we studied the incidence of anatomical 70 
abnormalities found on CT imaging of lung cancer patients 12 months after RT, compared to their 
pre-treatment CT. This study is the first step toward developing a CT-based scoring system for RILD. 
The aim was to describe key radiological findings to inform the diagnosis of RILD.  
 




Patient data were derived from the IDEAL CRT trial cohort [11]. This was a stage I/II clinical trial of 
isotoxic chemoradiation for patients with stage II-III non-small cell lung cancer (NSCLC). Patients 80 
received 63-73Gy RT in 30 fractions over 6 weeks or 63-71Gy in 30 fractions over 5 weeks (with one 
day of twice daily RT weekly) with two concurrent cycles of cisplatin and vinorelbine. The lung 
EQD2mean dose was planned to be 18.2Gy in all patients, so that although the tumour dose varied 
between patients, the lung dose was homogeneous across the entire cohort. The protocol called for CT 
scans to be performed at 12 months post-RT in all patients. Median overall survival (OS) for the 6-85 
week protocol was 36.9 months. The 5-week outcomes are pending full follow-up. Baseline and 12 
month CT scans were collected centrally. Information on tumour stage, recurrence status and patient 
characteristics are presented in Table 1.  
 
CT scans 90 
 
Each patient underwent a baseline PET/CT or diagnostic CT before treatment and a diagnostic CT 12 
months after treatment. Pairs of baseline and follow-up CT images were rigidly co-registered using 
the open-source NiftyReg software [30]. The transformation was optimised to match the anatomy of 
the thoracic vertebrae.  95 
 
Scoring of radiological findings of RILD  
 
Analysis of CT abnormalities was achieved by consensus in a multidisciplinary team: AD, thoracic 
radiologist, DL, clinical oncologist and CV, medical physicist. Scans were inspected in pairs (baseline 100 
vs follow-up) to assess new findings indicative of lung damage. There was no knowledge of the 
patient’s identity or RT treatment details. Window and level settings were the same for all images 
(W=1300, L=-350). The abnormalities identified were categorised as follows: (1) parenchymal, (2) 
lung volume reduction, and (3) pleural.  
 105 
Classification of radiological changes  
 
Parenchymal findings of four types were noted as defined in Gotway et al (2005) (Figure 1): ground-
glass opacities (GGO), consolidation, reticulation and traction bronchiectasis [31]. Since rounded 
consolidation and residual masses may have a similar radiological appearance [32,33], residual 110 
masses were defined as opacities with rounded shape in the same anatomical location of the initial 
tumour. Follow-up clinical and imaging data from the trial were used to identify residual masses with 
local recurrence.   
 
Lung volume reduction measurement was recorded in five ways (Figure 2): reduction in lung height, 115 
distortion of ipsilateral pleural fissure anatomy, changes in the position and shape of the ipsilateral 
hemidiaphragm [23], displacement and/or thickening of the anterior pleural junction line[34], and 
gross distortions of the anatomy of the main bronchi. Reduction in lung height was assessed on 
coronal reconstructed images. Fissure distortion was identified through changes in the relationship 
between the oblique fissure and diaphragm on axial images. Distortions of the bronchial tree were 120 
identified on coronal views.  
 
Pleural changes included thickening and effusion (Figure 3). Effusion is a region of homogeneous 
liquid at the boundary between the lung and thoracic cage. Thickening is an increase in the size of the 
pleural reflection, with the intensity of soft tissue and occurring at any interface between lung and 125 
thoracic cage.   
 
In total three categories and eleven sub-categories of lung damage were analysed. For each patient, 
the presence or absence of each category and sub-category was annotated. Qualitative details on sub-
types of patterns of damage were also recorded for future analysis. For the purposes of this analysis 130 





Out of 120 patients in IDEAL CRT, baseline and 12-month scans were available for central review in 
33 patients at the time of this analysis. All available pairs of baseline and 12-month scans were 
reviewed by the multidisciplinary team. For a total of six patients there was radiological evidence of 
major radiation damage that did not correspond to typical RILD. In five patients there was partial lung 
collapse due to airways damage. One patient had a lung abscess with extensive inflammatory change. 140 
These anatomical changes obscure the described findings of RILD. 27 patients are included in this 
analysis. The median time from end of treatment to time of second scan was 353 days, range: 265-367 
days.  
 
The number of patients with each category and sub-category of change is shown in Figure 4. 145 
Parenchymal changes were detected in all patients and volume reduction in all patients but one. 
Pleural changes were found in 82% of patients. All patients had at least two categories of lung 
damage and all three categories were present in 78% of patients.  
 
Within the parenchymal category, the sub-category of consolidation was most commonly present, 150 
affecting 93% of patients. GGOs, reticulation and traction bronchiectasis were present in 37%, 52% 
and 44% of patients respectively. 
 
In the volume reduction category, fissure and diaphragm distortion were present in 78% and 67% of 
patients respectively. Lung height was reduced in 59%. Major airways distortion and anterior 155 
junctional change were present in 63% and 78% respectively, representing mediastinal change.  
Pleural thickening was present in 70% and pleural effusion in 19%.  
 
Table 2 shows more information regarding the patterns of damage and incidence for each sub-




We performed a systematic assessment of RILD changes on CT scans acquired 12 months following 
radical CRT for NSCLC. The analysis was performed on scans from a prospective cohort of 165 
homogeneously treated patients within the IDEAL CRT study. IDEAL CRT made use of modern RT 
technologies, namely planning on 3D or 4D-CT imaging based planning, 3D-CRT or IMRT treatment 
delivery, and limited mean lung dose. Based purely on radiological findings, all patients had evidence 
of lung damage at 12 month of follow-up, with variable levels of severity. RILD is a common but 
often asymptomatic consequence of lung RT. Our findings demonstrate the extent to which it is 170 
under-reported across centers and trials. While different sub-categories of damage can also be 
encountered in other diseases, the patterns of change are quite different from other forms of lung 
damage [31,35]. These findings will be useful in differentiating RILD from other lung diseases.  
 
The presence of radiation damage in all patients is a key finding of this study. In IDEAL CRT, the 175 
target dose was escalated from 63 to 73 Gy, which might explain the high incidence of radiological 
findings of RILD. However, for the reported cohort, patients with higher prescribed doses did not 
have higher numbers of sub-categories of RILD. Further investigation, comparing the incidence and 
severity of RILD in larger cohorts with varying treatment prescriptions is required.  
 180 
Three key categories of change were identified on CT: lung parenchymal changes, lung volume 
reduction and pleural effusion or thickening. These were present in 100%, 96% and 82% of patients 
respectively and 78% of patients had all three categories of change. These changes are therefore 
frequently identified in RILD. Specific forms of parenchymal CT change, such as GGOs, reticulation 
and traction bronchiectasis, occur with sufficient frequency to be consistent with RILD.  185 
 
Mah et al (1986) reported 6-month changes after non-conformal radical RT. They found that 
parenchymal changes (air bronchograms, present in 25%), loss of lung volume (15%) and pleural 
thickening (15%) were common findings. CT scan slices were at 1cm thickness and the quality of the 
scans was likely not up to modern standards. Less than half of the patients were treated for NSCLC 190 
and there was no record of how reduction in lung volume was defined. Kroenig et al (2001) studied 19 
NSCLC patients after radical conformal RT of 69.6Gy to 90Gy. They too found evidence of RT 
damage in all patients, concentrating on parenchymal lung changes.  
 
Parenchymal damage is of core interest in RILD as the lung is the key organ at risk. We have 195 
described various parenchymal changes which likely manifest according to the predominant process 
of damage in individual patients. GGOs have been interpreted as inflammatory but might also be 
fibrotic [17,36,37]. Reticulation and traction bronchiectasis are interpreted as fibrotic and are core 
diagnostic findings in idiopathic pulmonary fibrosis [35]. Consolidation could represent either an 
inflammatory or fibrotic processes and might be a common radiological endpoint for both. It is likely 200 
that RILD is a process with both chronic inflammatory and fibrotic mechanisms reflected in the 
radiological findings. This has been described in diffuse pulmonary fibrotic diseases [15].  
 
The distinction between radiotherapy induced inflammatory and fibrotic changes on CT has 
sometimes been defined by time. That is, changes before 6 months are described as most likely 205 
representing inflammation and those beyond 12 months most likely fibrotic [21,29]. The period of 6 
to 24 months is often accepted as the period of stabilisation of fibrosis [17,38]. This paper describes 
CT changes 12 months following RT, a time point by which one might predict there to be little or no 
residual inflammatory changes. We have described significant consolidation and GGOs at 12 months. 
Whether these findings represent significant ongoing inflammation or areas of fibrosis is uncertain. A 210 
review of CT scans at 24 months is required to verify whether these changes persist or resolve. 
Identifying the presence of a chronic inflammatory process is important because it offers the 
possibility of successful intervention to reduce the extent of RILD even at a relative late stage.  
 
Lung volume reduction as demonstrated by visible lung volume and mediastinal changes was evident 215 
in almost all patients (96%). Volume loss reflects fibrotic change including extensive microscopic 
fibrosis not apparent with standard CT imaging. It remains to be seen whether more quantitative 
measures of volume loss on CT necessarily correlate with clinical markers of lung damage.  
  
The commonly observed finding of pleural changes has not been previously recognised as a classic 220 
RILD finding [5,6]. Clinical pleural syndromes are not commonly reported after RT. It is unknown 
whether these changes are caused by direct RT damage or through a reaction to parenchymal lung 
changes.  
 
RILD scoring systems are based on clinical, radiological and functional criteria, such as the Radiation 225 
Therapy Oncology Group and European Organization for Research and Treatment of Cancer 
(RTOG/EORTC) late radiation morbidity scoring system, and the Common Terminology Criteria for 
Adverse Events (CTCAE) [39,40]. Based on our findings the radiological components of these 
systems may be inadequate. RTOG/EORTC criteria score non-specified ‘radiological changes’ as 
either slight, patchy or dense. CTCAE scores pulmonary fibrosis radiologically on the extent of 230 
‘radiological pulmonary fibrosis’ from <25% to <75% and adds ‘honeycombing’ in grade 4. These 
criteria may well be appropriate for other causes of pulmonary fibrosis but seem inappropriate for use 
in RILD. Radiology-only scoring systems have been proposed based on qualitative assessments of CT 
intensity and texture changes. These have mostly been applied in the context of conventionally 
fractionated RT for early follow-up scans (≤6 months) [5,41] or multiple time-points over 36 months 235 
[6,18]. There are also studies following stereotactic RT that score RILD in terms of consolidation sub-
types [20,22,42,43]. In these studies only parenchymal changes are considered. In stereotactic 
delivery the lung volumes irradiated are considerably smaller, and hence a radiological-system 
looking only at parenchymal consolidation is likely adequate. We have demonstrated that indirect 
signs of lung volume loss characterized by a variety of anatomical deformities, as well as the 240 
identification of pleural abnormalities, may be critical in diagnosing RILD following conventionally 
fractionated RT.  
 
The spatial relationship between RILD and radiation dose is crucial and requires further detailed 
research investigating both local dose and global lung doses. We are exploring co-registration of 245 
images to propagate planning isodose surfaces [44,45]. Parenchymal changes seem to occur in areas 
of higher dose (approximately 40Gy and greater). Anatomical distortion and pleural reactions reflect 
dose delivered in distant anatomical locations. The lung doses in IDEAL CRT were relatively 
homogeneous, and dose relationship studies require advanced statistical methods such as principal 
component analysis of DVHs and permutation testing [46,47].  250 
 
Our study has limitations. We have used an exhaustive examination of a relatively small cohort to 
define the key parameters with which to interrogate future large numbers. Another limitation is that 
the initial clinical trial was not designed to identify symptoms specific to the findings that we have 
now described. Lung function, MRC breathing score and performance status are available and will be 255 
investigated. More specific questions would be required to fully examine the clinical impact of RILD 
CT changes.  
 
We have demonstrated that RILD changes occur in all patients following radical RT for NSCLC. We 
have purposely limited our study to clinically identifiable radiological changes aiming to describe 260 
them in a manner potentially transferrable to the clinic. We believe this is the first step towards 
generating a validated radiological scoring system that is objective, clinically sound, easily 
interpretable, repeatable and user independent that provides relevant information on RILD. To date 
there is still no objective scoring systems of long term RILD which leads to variability in reporting of 
toxicity amongst trials [48]. In the case of pneumonitis studies, other groups have worked on 265 
developing deformable image registration based methods to measure local changes in the 
parenchymal texture, which correlate well with radiologist scores of pneumonitis [49,50]. However, 
as found in this study, long term RILD causes both complex changes in the lung parenchyma and 
distortions on thoracic anatomy. These changes pose a difficult challenge for image registration, 
described by our group elsewhere [45]. Next steps include developing objective quantification 270 
methods using image analysis techniques independent of image registration [51,52] and correlating 
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Figure and table captions 
 
  No. Patients 
(N=27) 
Age (y)  
 ≥70 5 
 <70 22 
 Mean (±SD) 66 (±7) 
 Median (range) 65 (53-83) 
Sex  
 Male 20 
 Female 7 
Stage  
 IIA 0 
 IIB 1 
 IIIA 17 
 IIIB 9 
Fractionation scheme  
 6-weeks protocol 17 
 5-weeks protocol 10 
Radiotherapy technique  
 Conformal 24 
 IMRT/VMAT 3 
GTV size* (cm3)  
 Mean (±SD) 104 (±57) 
 Median (range) 101 (14-211) 
PTV size* (cm3)  
 Mean (±SD) 400 (±149) 
 Median (range) 358 (202-832) 
Prescription dose (Gy)  
 Mean (±SD) 67.9 (±3.8) 
 Median (range) 69.1 (63.0-73.0) 
*calculated on 3D or 4D-CT used for planning. On 4D-CT a composite volume 
was formed by merging the GTV outlined on different phases. 
Table 1- Demographics and baseline characteristics of all patients. 
 
 300 
Figure 1- Patterns of parenchymal change. (a) Low volume of consolidation; (b) High volume of 
consolidation. (c) Consolidation accompanied by a distorted airway in keeping with traction 
bronchiectasis. (d) Cavitating consolidation. (e) Residual mass surrounded by consolidation. (f) 
Ground-glass opacities. (g)(h)(i) Examples of reticulation patterns. 
 305 
Figure 2- Lung volume reduction (left: pre-treatment scan, right: 12-month follow-up scan). (a) 
Marked distortion of the fissure in the absence of consolidation. (b) Distortion of fissures 
accompanied by consolidation, volume loss and aggravation of pre-existing diaphragmatic tenting. (c) 
Diaphragmatic tenting combined with mild elevation, and pleural thickening at the fissure. (d) 
Elevation of the diaphragm, combined with elevation of the left upper main bronchus. (e) Left main 310 
bronchi pulled upward, together with minor diaphragmatic elevation and tenting. (f) Rotation and 
thickening of the anterior junction line. 
 Figure 3- Pleural reactions. (a) Pleural thickening. (b) Pleural effusion. 
  315 
 Change No. of Patients 
(N=27) 
Parenchymal  27 
Consolidation 25 
 of which  
  Cavitation 2 
Ground-glass opacities 12 
Traction bronchiectasis 10 
Reticulation 14 
 of which  
  Focal linear opacities 11 
  Band opacities 3 
Residual mass 7 
 of which  
  Local recurrence 5* 
    
Volume reduction 26 
Reduction in lung height 16 
Fissure distortion 21 
 of which  
  Pulled forward 14 
  Pulled backward 5 
  Pulled upward 6 
  Pulled medially 2 
  Flipped 1 
Diaphragm distortion 18 
 of which  
  Elevation 7 
  Tenting 13 
  Changes in curvature 5 
Anterior junction line distortion 21 
 of which  
  Rotation 18 
  Thickening 15 
Major airways distortion 17 
 of which  
  Pulled upward 13 
  Pulled downward 2 
  Stenosis 1 
    
Pleural reactions 22 
Thickening 17 
Effusion 3 
Thickening and effusion 2 
*confirmed with trial follow-up data  
Table 2- Frequency of each sub-type of lung damage. 
 
 Figure 4 - (a) Incidence of different categories and sub-categories of change at 12-months after 320 
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